Aldeyra Therapeutics, Inc. - Common Stock (ALDX)
5.9000
+0.1900 (3.33%)
Aldeyra Therapeutics is a biotechnology company focused on developing and commercializing innovative therapies to treat immune-mediated and metabolic diseases
The company is particularly known for its research in ocular disorders and rare diseases, utilizing its proprietary platform to create novel compounds that aim to modulate immune responses and address unmet medical needs. Aldeyra is committed to advancing its therapeutic pipeline through clinical trials, bringing potential new treatment options to patients facing debilitating health conditions.
Previous Close | 5.710 |
---|---|
Open | 5.730 |
Bid | 5.900 |
Ask | 5.930 |
Day's Range | 5.710 - 5.992 |
52 Week Range | 2.710 - 6.548 |
Volume | 215,981 |
Market Cap | 345.60M |
PE Ratio (TTM) | -7.867 |
EPS (TTM) | -0.8 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 318,957 |
News & Press Releases
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference. The conference is being conducted virtually on February 11, 2025.
By Aldeyra Therapeutics, Inc. · Via Business Wire · February 4, 2025
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in the Eyes Wide Open on Ophthalmology Panel at the Citi 2024 Global Healthcare Conference. The conference is being conducted in Miami, Florida December 2-5, 2024.
By Aldeyra Therapeutics, Inc. · Via Business Wire · December 2, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025. In conjunction with the acceptance of the NDA for review, Aldeyra announced the expansion of its exclusive option agreement with AbbVie Inc. (AbbVie).
By Aldeyra Therapeutics, Inc. · Via Business Wire · November 18, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference 2024. The conference is being conducted in London, England November 19- 21, 2024.
By Aldeyra Therapeutics, Inc. · Via Business Wire · November 14, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Tomasz Stryjewski, M.D., Chief Medical Advisor - Retina, will present at the Disruptive Innovations Symposium during the Ocular Surgery News (OSN) New York Retina 2024 Meeting, which takes place in New York, New York November 8-10, 2024.
By Aldeyra Therapeutics, Inc. · Via Business Wire · October 31, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. The resubmission includes previously disclosed positive results from a recently completed dry eye disease symptom trial requested by the FDA following review of the previously submitted NDA, as well as a draft label reflecting acute activity in reducing dry eye symptoms in a dry eye chamber trial, chronic activity in reducing dry eye symptoms in a field trial, and acute activity in reducing ocular redness in two dry eye chamber trials.
By Aldeyra Therapeutics, Inc. · Via Business Wire · October 3, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference.
By Aldeyra Therapeutics, Inc. · Via Business Wire · September 5, 2024
![](https://cdn.benzinga.com/files/images/story/2024/08/08/Invest-In-Biotech.jpeg?width=1200&height=800&fit=crop)
Aldeyra Therapeutics announces successful results from its Phase 3 clinical trial of reproxalap. The results support a potential 2024 NDA resubmission.
Via Benzinga · August 8, 2024
![](https://mms.businesswire.com/media/20240808408806/en/2210589/22/Slide1.jpg)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease. Reproxalap was statistically superior to vehicle for the prespecified primary endpoint of ocular discomfort (P=0.004), a U.S. Food and Drug Administration (FDA)-accepted symptom of dry eye disease.
By Aldeyra Therapeutics, Inc. · Via Business Wire · August 8, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, August 8, 2024, at 9:00 a.m. (ET) to provide top-line results from the Phase 3 dry eye disease clinical trial of reproxalap.
By Aldeyra Therapeutics, Inc. · Via Business Wire · August 7, 2024
![](https://mms.businesswire.com/media/20240620180926/en/2165071/22/Aldeyra_6.jpg)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced advancement of new RASP modulators and recent preclinical data in obesity in conjunction with an Investor Roundtable scheduled to begin at 8:00 a.m. ET today.
By Aldeyra Therapeutics, Inc. · Via Business Wire · June 20, 2024
![](https://mms.businesswire.com/media/20240613335679/en/2158703/5/Aldeyra_Graphic_6.12.2024.jpg)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the completion of enrollment in a Phase 3 dry eye chamber clinical trial of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease. The trial is designed to enable potential resubmission of a dry eye disease New Drug Application (NDA) in the second half of 2024.
By Aldeyra Therapeutics, Inc. · Via Business Wire · June 13, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that the company will host an Investor Roundtable Q&A via webcast on Thursday, June 20, 2024 at 8:00 a.m. ET.
By Aldeyra Therapeutics, Inc. · Via Business Wire · June 12, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference.
By Aldeyra Therapeutics, Inc. · Via Business Wire · May 29, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced enrollment of the first patient in a Phase 3 dry eye chamber clinical trial designed to enable a potential resubmission of the New Drug Application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease.
By Aldeyra Therapeutics, Inc. · Via Business Wire · May 8, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
ALDX stock results show that Aldeyra Therapeutics met analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 3, 2024
![](https://mms.businesswire.com/media/20240425445928/en/2109144/5/Aldeyra_Obesity_Graph.jpg)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa.
By Aldeyra Therapeutics, Inc. · Via Business Wire · April 25, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that the company will host a Research & Development Day from 9:00a.m. to 1:00p.m. ET on Thursday, April 25, 2024 in New York City.
By Aldeyra Therapeutics, Inc. · Via Business Wire · April 18, 2024
![](https://cdn.benzinga.com/files/images/story/2024/04/04/image38.jpeg?width=1200&height=800&fit=crop)
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · April 4, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable resubmission of a New Drug Application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease to the U.S. Food and Drug Administration (FDA). Following discussions with the FDA, Aldeyra intends to initiate a dry eye chamber clinical trial in the first half of 2024. Contingent on positive results from the planned clinical trial, NDA resubmission is expected in the second half of 2024. Based on FDA guidance, the planned review period for the potential NDA resubmission is expected to be six months.
By Aldeyra Therapeutics, Inc. · Via Business Wire · March 28, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · March 5, 2024
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Aldeyra Therapeutics, Inc. (NASDAQALDX) on behalf of long-term stockholders following a class action complaint that was filed against Aldeyra on July 31, 2023 with a Class Period from March 17, 2022 to June 20, 2023. Our investigation concerns whether the board of directors of Aldeyra have breached their fiduciary duties to the company.
By Bragar Eagel & Squire · Via GlobeNewswire · February 9, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The conference will be held virtually on February 13-14, 2024.
By Aldeyra Therapeutics, Inc. · Via Business Wire · February 6, 2024
![](https://mms.businesswire.com/media/20240104883191/en/1987935/5/Slide.jpg)
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced advancement of its RASP modulator platform, including the expected submission to the FDA of a proposed expansion of the Phase 2 clinical trial of the investigational RASP modulator ADX-629 in Sjögren-Larsson Syndrome to include pediatric patients, initiation of a Phase 2 clinical trial of ADX-629 in moderate alcoholic hepatitis, submission of an IND application of the investigational RASP modulator ADX-246 for a Phase 1 clinical trial that is expected to be expanded to include atopic dermatitis patients, anticipated submission of an IND application of the investigational RASP modulator ADX-248 for a Phase 1/2 clinical trial in patients with the dry form of age-related macular degeneration (AMD) and dark adaptation deficit, and initiation of a preclinical program of RASP modulators in metabolic disease.
By Aldeyra Therapeutics, Inc. · Via Business Wire · January 4, 2024
![](https://cdn.benzinga.com/files/images/story/2023/12/19/ardx.png?width=1200&height=800&fit=crop)
Aldeyra Therapeutics Inc (NASDAQALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in
Via Benzinga · December 19, 2023